{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-003323","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2024-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.459167+00:00","generated_at":"2026-06-01T05:51:53.104307+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arbutus announces positive Phase 2a data for imdusiran + VTP-300 in chronic HBV","bullets":["Imdusiran + VTP-300 achieved statistically significant (p<0.05) lower HBsAg at 24 weeks post-EOT vs placebo.","80% treatment arm vs 16% placebo had HBsAg <100 IU/mL; 60% vs 0% <10 IU/mL at 24 weeks post-EOT.","84% of treatment arm patients met NA therapy discontinuation criteria vs 53% in placebo arm.","Treatment generally safe; no SAEs or Grade 3/4 AEs; injection-site reactions and transient ALT increases.","Additional cohort evaluating nivolumab combination fully enrolled; preliminary data expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-003323","json":"https://secwatch.observer/filing/0001171843-24-003323.json","markdown":"https://secwatch.observer/filing/0001171843-24-003323.md","text":"https://secwatch.observer/filing/0001171843-24-003323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324003323/0001171843-24-003323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324003323/f8k_060524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:51:53.104307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}